Engineering of fragment crystallizable (Fc) domains of therapeutic immunoglobulin (IgG)
antibodies to eliminate their immune effector functions while retaining other Fc …

Self-reactive antibodies represent a significant force in autoimmune disease induction. In
antibody-dependent autoimmune syndromes such as immune thrombocytopenia (ITP) …

In recent years, there has been a surge in the research and development of novel molecules
as potential therapeutic alternatives to traditional treatments (such as intravenous …

Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated
immune responses with cellular effector functions. A high resolution map of the binding site …

The antibody Fc region regulates antibody cytotoxic activities and serum half-life. In a
therapeutic context, however, the cytotoxic effector function of an antibody is often not …

Antibody-dependent cellular cytotoxicity (ADCC) is one of the important mechanisms of
action of the targeting of tumor cells by therapeutic monoclonal antibodies (mAbs). Among …

Protein-or glyco-engineering of antibody molecules can be used to enhance Fc-mediated
effector functions. ScFv-Fc fusion proteins (scFv-Fc) represent interesting antibody …

In recent years, therapy with monoclonal antibodies has become standard of care in various
clinical applications. Despite obvious clinical activity, not all patients respond and benefit …

Monoclonal antibodies (mAb) are widely used in the treatment of non-Hodgkin's lymphoma
and autoimmune diseases. Although the mechanism of action in vivo is not always known …

The binding sites on human IgG1 for human Fcγ receptor (FcγR) I, FcγRIIa, FcγRIIb, FcγRIIIa
and neonatal FcR have been mapped. A common set of IgG1 residues is involved in binding …